GE Healthcare Technologies Inc (1GEHC) Price & Analysis
1GEHC Stock Chart & Stats
- Day’s Range
- EUR 69.00 - EUR 69.00
- 52-Week Range
- EUR 29.00 - EUR 111.00
- Previous Close
- EUR 68.93
- Volume
- 175
- Average Volume (3M)
- 97
- Market Cap
- EUR 30.90B
- Enterprise Value
- EUR 37.42B
- Total Cash (Recent Filing)
- EUR 2.85B
- Total Debt (Recent Filing)
- EUR 10.41B
- Price to Earnings (P/E)
- 19.8
- Beta
- 0.71
- Next Earnings
- Feb 10, 2027
- EPS Estimate
- 1.39
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.19%
Bulls Say, Bears Say
Bulls Say
Broad-based Growth And Guidance
Broad-based revenue growth paired with significant EBIT and EPS expansion indicates improving operating leverage and strong execution across the portfolio. The raised full-year outlook reinforces management confidence that commercial momentum and productivity gains can support durable performance over the next several quarters.
Backlog And Order Visibility
A growing backlog and sustained order expansion provide visibility into future equipment and service revenue, reducing reliance on any single quarter’s purchasing decisions. This supports medium-term planning, capacity utilization, and conversion of demand into revenue across GE Healthcare’s business segments.
Pharmaceutical Diagnostics Growth
Pharmaceutical Diagnostics combines strong growth with high segment profitability and repeat demand linked to imaging procedures. Continued radiopharmaceutical adoption and precision-medicine applications broaden the company’s technology platform, creating attractive opportunities for recurring utilization and portfolio expansion.
Bears Say
Profitability And Cash-conversion Pressure
Recent deterioration in net margin and cash conversion suggests that reported earnings are translating less efficiently into cash, despite positive free cash flow. If this persists, it could constrain internal funding for innovation, debt reduction, and shareholder returns while increasing sensitivity to cost pressures.
Meaningful Leverage
Leverage has improved but remains meaningful relative to the equity base, which reduces financial flexibility compared with a lightly indebted balance sheet. Debt obligations can limit capital-allocation choices and make the company more vulnerable if profitability or cash generation weakens during an equipment-cycle slowdown.
Patient Care Solutions Execution Risk
Although Patient Care Solutions has improved fulfillment and margins, unresolved operational recovery work still creates execution risk in a key segment. Continued issues with components, capacity planning, or customer-site timing could delay backlog conversion, disrupt service levels, and limit the durability of recent improvement.
1GEHC FAQ
What was GE Healthcare Technologies Inc’s price range in the past 12 months?
What is GE Healthcare Technologies Inc’s market cap?
When is GE Healthcare Technologies Inc’s upcoming earnings report date?
How were GE Healthcare Technologies Inc’s earnings last quarter?
Is GE Healthcare Technologies Inc overvalued?
Does GE Healthcare Technologies Inc pay dividends?
What is GE Healthcare Technologies Inc’s EPS estimate?
How many shares outstanding does GE Healthcare Technologies Inc have?
What happened to GE Healthcare Technologies Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GE Healthcare Technologies Inc?
What is the TipRanks Smart Score and how is it calculated?
GE Healthcare Technologies Inc Stock Smart Score
Company Description
GE Healthcare Technologies Inc
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Peter J. Arduini
- Employees
- 54,000
- Website
- www.gehealthcare.com
- Address
- 500 West Monroe Street, Chicago, IL, 60661, US
GE Healthcare Technologies Inc (1GEHC) Earnings & Revenues
1GEHC Company Deck
1GEHC Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Highlights significantly outweighed the lowlights, with strong organic revenue growth, broad-based segment performance, margin and EPS expansion, higher free cash flow, raised full-year guidance, regulatory progress, expanding radiopharmaceutical adoption, and confidence in the 2027 and 2028 outlook. The company acknowledged inflation, tariff uncertainty, PCS recovery work, China execution challenges, and generic competition, but management described mitigation actions and maintained confidence in the business trajectory.
View all IT:1GEHC earnings summaries1GEHC Net sales Breakdown
- 44.82% Imaging
- 25.96% AVS
- 14.96% PCS
- 14.06% PDx
- 0.19% Other
1GEHC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |